{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:16:00Z","timestamp":1778793360775,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No 82170172 and 82170222"],"award-info":[{"award-number":["Grant No 82170172 and 82170222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07010-3","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:11Z","timestamp":1777688531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD135 (FLT3 receptor) expression as an indicator of prognosis in patients with de novo acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Jinhong","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"7","key":"7010_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) \u2018Acute myeloid leukemia: a comprehensive review and 2016 update.\u2019 Blood Cancer J 6(7):e441\u2013e441. https:\/\/doi.org\/10.1038\/bcj.2016.50","journal-title":"Blood Cancer J"},{"issue":"12","key":"7010_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"1","key":"7010_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00487-6","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W et al (2024) Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol 13(1):16. https:\/\/doi.org\/10.1186\/s40164-024-00487-6","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"7010_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C et al (2023) Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 37(6):1234\u201344. https:\/\/doi.org\/10.1038\/s41375-023-01884-2","journal-title":"Leukemia"},{"issue":"1","key":"7010_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2324417","volume":"29","author":"M Kim","year":"2024","unstructured":"Kim M, Ahn SY, Kim T, Jung SH, Song GY, Yang DH et al (2024) Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine. Hematology 29(1):2324417. https:\/\/doi.org\/10.1080\/16078454.2024.2324417","journal-title":"Hematology"},{"issue":"21","key":"7010_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u201373. https:\/\/doi.org\/10.1182\/blood.2024025409","journal-title":"Blood"},{"issue":"5","key":"7010_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100(5):860\u201391. https:\/\/doi.org\/10.1002\/ajh.27625","journal-title":"Am J Hematol"},{"issue":"5","key":"7010_CR8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB et al (2018) CAR T-cells targeting FLT3 have potent activity against FLT3\u2009\u2013\u2009ITD\u2009+\u2009AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32(5):1168\u20131179. https:\/\/doi.org\/10.1038\/s41375-018-0009-0","journal-title":"Leukemia"},{"issue":"6","key":"7010_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/bjh.18971","volume":"202","author":"JC Peschke","year":"2023","unstructured":"Peschke JC, Bergmann R, Mehnert M, Gonzalez Soto KE, Loureiro LR, Mitwasi N et al (2023) <Emphasis Type=\"SmallCaps\">FLT3<\/Emphasis> -directed <Emphasis Type=\"SmallCaps\">UniCAR<\/Emphasis> t\u2010cell therapy of acute myeloid leukaemia. Br J Haematol 202(6):1137\u201350. https:\/\/doi.org\/10.1111\/bjh.18971","journal-title":"Br J Haematol"},{"issue":"2","key":"7010_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u201322. https:\/\/doi.org\/10.1111\/cas.14274","journal-title":"Cancer Sci"},{"issue":"11","key":"7010_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112992","volume":"10","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Fischer M, Schnetzke U, Fortner C, Kirkpatrick J, Heidel FH et al (2021) Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance. Cells 10(11):2992. https:\/\/doi.org\/10.3390\/cells10112992","journal-title":"Cells"},{"issue":"1","key":"7010_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","volume":"106","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schw\u00e4ble J, Brandts C, Tickenbrock L, Sargin B, Kindler T et al (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106(1):265\u201373. https:\/\/doi.org\/10.1182\/blood-2004-07-2942","journal-title":"Blood"},{"issue":"2","key":"7010_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.arcmed.2020.10.013","volume":"52","author":"J Vela-Ojeda","year":"2021","unstructured":"Vela-Ojeda J, Cardenas PV, Garcia-Ruiz Esparza MA, Montiel Cervantes LA, Chavez JG, Caballero AH et al (2021) FLT3-ITD and CD135 over-expression are frequent findings of poor survival in adult patients with acute leukemias. Arch Med Res 52(2):217\u201323. https:\/\/doi.org\/10.1016\/j.arcmed.2020.10.013","journal-title":"Arch Med Res"},{"issue":"7","key":"7010_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"6","key":"7010_CR15","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H et al (2022) Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6):e415-24. https:\/\/doi.org\/10.1016\/S2352-3026(22)00106-5","journal-title":"Lancet Haematol"},{"issue":"13","key":"7010_CR16","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W et al (2024) Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3 -mutated AML. JCO 42(13):1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911","journal-title":"JCO"},{"issue":"12","key":"7010_CR17","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1080\/1042819021000040206","volume":"43","author":"K Osumi","year":"2002","unstructured":"Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K et al (2002) Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 43(12):2291\u20139. https:\/\/doi.org\/10.1080\/1042819021000040206","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"7010_CR18","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1182\/blood-2010-12-328302","volume":"117","author":"EA Coenen","year":"2011","unstructured":"Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al (2011) Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23\/MLL-rearranged AML patients: results of an international study. Blood 117(30):7102\u201311. https:\/\/doi.org\/10.1182\/blood-2010-12-328302","journal-title":"Blood"},{"issue":"8","key":"7010_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.clml.2018.05.014","volume":"18","author":"EZ Kandeel","year":"2018","unstructured":"Kandeel EZ, El Sayed G, Elsharkawy N, Eldin DN, Nassar HR, Ibrahiem D et al (2018) Impact of FLT3 receptor (CD135) detection by flow cytometry on clinical outcome of adult acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk 18(8):541\u20137. https:\/\/doi.org\/10.1016\/j.clml.2018.05.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7010_CR20","unstructured":"Rappold I, Ziegler BL, K\u00f6hler I, Marchetto S, Rosnet O, Birnbaum D et al Functional and Phenotypic Characterization of Cord Blood and Bone Marrow Subsets Expressing FLT3 (CD135) Receptor Tyrosine Kinase"},{"issue":"15","key":"7010_CR21","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-16-2353","volume":"23","author":"K Tarlock","year":"2017","unstructured":"Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R et al (2017) Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Clin Cancer Res 23(15):3649\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2353","journal-title":"Clin Cancer Res"},{"key":"7010_CR22","doi-asserted-by":"publisher","unstructured":"Cheng J, Qu L, Wang J, Cheng L, Wang Y (2017 Dec) High expression of FLT3 is a risk factor in leukemia. Mol Med Rep 8. https:\/\/doi.org\/10.3892\/mmr.2017.8232","DOI":"10.3892\/mmr.2017.8232"},{"issue":"10","key":"7010_CR23","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","volume":"36","author":"R Ranieri","year":"2022","unstructured":"Ranieri R, Pianigiani G, Sciabolacci S, Perriello VM, Marra A, Cardinali V et al (2022) Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia 36(10):2351\u201367. https:\/\/doi.org\/10.1038\/s41375-022-01666-2","journal-title":"Leukemia"},{"issue":"30","key":"7010_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K D\u00f6hner","year":"2020","unstructured":"D\u00f6hner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA et al (2020) Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 135(30):371\u201380. https:\/\/doi.org\/10.1182\/blood.2019002697","journal-title":"Blood"},{"issue":"15","key":"7010_CR25","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J et al (2024) Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML. Blood 144(15):714\u201328. https:\/\/doi.org\/10.1182\/blood.2024024310","journal-title":"Blood"},{"issue":"10","key":"7010_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO-24-01715","volume":"43","author":"C Tregnago","year":"2025","unstructured":"Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D et al (2025) Influence of nucleophosmin ( NPM1 ) genotypes on outcome of patients with AML: an AIEOP-BFM and COG-SWOG intergroup collaboration. JCO 43(10):972\u201384. https:\/\/doi.org\/10.1200\/JCO-24-01715","journal-title":"JCO"},{"key":"7010_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01103-w","author":"Y Yao","year":"2024","unstructured":"Yao Y (2024) Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-024-01103-w","journal-title":"Blood Cancer J"},{"issue":"4","key":"7010_CR28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1743-7563.2010.01322.x","volume":"6","author":"HH Vora","year":"2010","unstructured":"Vora HH, Shukla SN, Brahambhatt BV, Mehta SH, Patel NA, Parikh SK et al (2010) Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asia-Pac J Clin Oncol 6(4):306\u201319. https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01322.x","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"17","key":"7010_CR29","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T et al (2023) Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv 7(17):5122\u201331. https:\/\/doi.org\/10.1182\/bloodadvances.2023010173","journal-title":"Blood Adv"},{"issue":"15","key":"7010_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP (2020) NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 136(15):1707\u20131721. https:\/\/doi.org\/10.1182\/blood.2019004226","journal-title":"Blood"},{"key":"7010_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103126","volume":"62","author":"TT Ma","year":"2020","unstructured":"Ma TT, Lin XJ, Cheng WY, Xue Q, Wang SY, Liu FJ et al (2020) Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. eBioMedicine 62:103126. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103126","journal-title":"eBioMedicine"},{"issue":"38(11)","key":"7010_CR32","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41375-024-02369-6","volume":"2024 Nov","author":"Toma Monika M","year":"2024","unstructured":"Toma MM, Skorski T (2024). Star wars against leukemia: attacking the clones. Leukemia 38(11):2293\u20132302. https:\/\/doi.org\/10.1038\/s41375-024-02369-6","journal-title":"Leukemia"},{"issue":"3","key":"7010_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.103476","volume":"105","author":"T Kirtek","year":"2025","unstructured":"Kirtek T, Chen W, Harris J, Bagg A, Foucar K, Tam W et al (2025) 1240 acute leukemias of ambiguous lineage with RUNX1 mutations show similar prognosis compared to acute myeloid leukemia with RUNX1 mutations: a study from the bone marrow pathology group. Lab Invest 105(3):103476. https:\/\/doi.org\/10.1016\/j.labinv.2024.103476","journal-title":"Lab Invest"},{"issue":"12","key":"7010_CR34","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3109\/10428194.2014.893308","volume":"55","author":"WJ Liu","year":"2014","unstructured":"Liu WJ, Tan XH, Luo XP, Guo BP, Wei ZJ, Ke Q et al (2014) Prognostic significance of Tet methylcytosine dioxygenase 2 ( TET2 ) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leuk Lymphoma 55(12):2691\u20138. https:\/\/doi.org\/10.3109\/10428194.2014.893308","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07010-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:02:20Z","timestamp":1778792540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07010-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7010"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07010-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University (No. 2024747) and written informed consent was obtained from all participants as part of routine hospital procedure before the isolation and usage of these samples in this retrospective study. The research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}},{"value":"Written informed consent for publication was obtained from all of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}